Suresh Palaniswamy

US Patent:

20050181052, Aug 18, 2005

Filed:

Feb 17, 2004

Appl. No.:

10/779933

Inventors:

Satishkumar Patel - West Windsor NJ, US
Indranil Nandi - Plainsboro NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Pablo Davila - East Windsor NJ, US

International Classification:

A61K031/4439
A61K009/48
A61K009/20
A61K009/24

US Classification:

424472000, 514338000

Abstract:

A pharmaceutical composition comprising microtablets, wherein said microtablets comprise lansoprazole, a lubricant, optionally one or more excipients, and an enteric coating, wherein the weight ratio of lansoprazole to lubricant is from about 1:4 to about 8:1, wherein said microtablets have a tablet size of about 1 mm to about 4 mm, and a tablet weight of 1 to 50 mg, and said microtablets are free of a separating or intermediate layer between the lansoprazole and enteric coating.

US Patent:

20050266082, Dec 1, 2005

Filed:

May 13, 2005

Appl. No.:

11/129451

Inventors:

Satishkumar Patel - West Windsor NJ, US
Pablo Davila - East Windsor NJ, US
Suresh Palaniswamy - East Windsor NJ, US

International Classification:

A61K031/137
A61K009/14
A61K009/16

US Classification:

424484000, 514649000, 424488000

Abstract:

A pharmaceutical composition comprising a hydrophobic matrix comprised of paroxetine HCl and a lipid component is provided. The matrix also preferably contains hydrophilic polymers, e.g., hypromellose. This invention also relates to a method of making such a composition by melt granulating paroxetine HCl with a molten binder comprising a lipid component. This invention also relates to tablets which contain such a matrix as a core and which having an enteric coating surrounding said core.

US Patent:

20060127479, Jun 15, 2006

Filed:

Oct 8, 2004

Appl. No.:

10/961728

Inventors:

Natrajan Kumaraperumal - Monmouth Junction NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Pablo Davila - East Windsor NJ, US

International Classification:

A61K 9/24

US Classification:

424472000

Abstract:

A taste masked pharmaceutical composition comprising: (a) a core comprising a bitter tasting drug, such as cetirizine dihydrochloride; and (b) a coating comprising a pharmaceutically acceptable cationic co-polymer based on mono- or dialkylaminoalkyl methacrylate and neutral acrylic or methacrylic esters, wherein the alkyl group independently has 1 to 6 carbon atoms, wherein said coating is applied to the surface of said core. The taste masked pharmaceutical compositions of the invention may be prepared without using an organic solvent or a cyclodextrin.

US Patent:

20060182806, Aug 17, 2006

Filed:

Nov 7, 2005

Appl. No.:

11/268060

Inventors:

Mintong Guo - Plainsboro NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Ashish Patel - East Brunswick NJ, US
Chad Gassert - Bayonne NJ, US
Pablo Davila - East Windsor NJ, US

International Classification:

A61K 9/26

US Classification:

424470000

Abstract:

An extended-release pharmaceutical composition comprising a core and a coating, wherein said core comprises propranolol or a pharmaceutically acceptable salt thereof and at least one excipient, and said coating comprises at least one water-soluble polymer and at least one water-insoluble polymer, wherein said coating is heated at a temperature of about 30 C. to about 70 C. after being applied to said core.

US Patent:

20060210631, Sep 21, 2006

Filed:

Mar 21, 2005

Appl. No.:

11/085671

Inventors:

Ashish Patel - North Brunswick NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Pablo Davila - East Windsor NJ, US

International Classification:

A61K 9/26
A61K 36/47

US Classification:

424470000, 424731000

Abstract:

A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice; and (c) a second coating applied to the surface of the first coating.

US Patent:

20060247255, Nov 2, 2006

Filed:

May 2, 2005

Appl. No.:

11/119543

Inventors:

Satishkumar Patel - West Windsor NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Bhaskarbhai Patel - Edison NJ, US
Pablo Davila - East Windsor NJ, US

International Classification:

A61K 31/496

US Classification:

514253080

Abstract:

A method for preparing a stable gatifloxacin composition in oral dosage form, said method comprising: (a) mixing gatifloxacin or a pharmaceutically acceptable salt or hydrate thereof, a disintegrant, and a filler for a time sufficient to form a mixture; (b) compacting the mixture of Step (a) at a compaction force of about 1 kN to about 30 kN for a time sufficient to form a compact; (c) milling the compact of Step (b) to form a granulation; and (d) mixing the granulation of Step (c) with an effective amount of a lubricant for a time sufficient to produce a gatifloxacin composition having a tap density of at least about 0.50 g/mL.

US Patent:

20050008704, Jan 13, 2005

Filed:

Jul 11, 2003

Appl. No.:

10/618545

Inventors:

Anup Ray - Staten Island NY, US
Indranil Nandi - Plainsboro NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Pablo Davila - East Windsor NJ, US
Aakanksha Vora - Dayton NJ, US

International Classification:

A61K031/704
A61K031/56
A61K031/5513
A61K031/58

US Classification:

424486000, 514171000, 514649000, 514035000, 514221000, 514571000, 514616000, 514174000

Abstract:

The present invention provides a pharmaceutical composition having enhanced solubility comprising a drug and polyethylene glycol, wherein the ratio of polyethylene glycol to drug by weight is from about 0.2:1 to about 10:1, and the polyethylene glycol has a melting point of at least 37 C. The pharmaceutical compositions exhibit rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.